DexCom, Inc. (DXCM) Showcases Next-Gen CGM Features at EASD 2025

We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. DexCom, Inc. is one of them.

DexCom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) systems, continues to advance diabetes care with its flagship G6 and G7 devices, which provide real-time glucose tracking and data sharing. At EASD 2025, the company highlighted upcoming features aimed at improving health outcomes and cost-effectiveness, reinforcing its innovation strategy in biosensing technology. These developments have kept DXCM among the best healthcare stocks, despite recent challenges.

Financial performance remains strong, with second-quarter 2025 revenue rising 15.2% year-over-year and earnings per share beating analyst estimates. Analysts maintain a moderate to strong buy consensus on DXCM, with price targets nearing $100, citing robust demand for its CGM systems.

However, September brought challenges after a report alleged unauthorized design changes in the G7 system, linking the issue to severe safety risks, including hospitalizations and deaths. The controversy sparked an 11.76% stock drop and prompted a class action investigation by Pomerantz LLP into potential securities fraud claims.

While we acknowledge the potential of DXCM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.